Medical devices, healthcare technology and the business of care
PMA approval · P210011

xT CDx

Tempus AI, Inc. · Decision date Apr 28, 2023

MEDTECHLEDGER EXPLANATIONP210011

What did the FDA approve?

The FDA record for P210011 lists an approval decision dated 2023-04-28 for xT CDx, a qualitative NGS-based in vitro diagnostic device. Per the source statement, it detects substitutions (SNVs and MNVs) and INDELs in 648 genes, plus microsatellite instability status, using DNA from FFPE tumor tissue and from matched normal blood or saliva, in previously diagnosed cancer patients with solid malignant neoplasms.

The stated intended uses include companion diagnostic identification of patients who may benefit from therapies listed in the Companion Diagnostic Indications table per approved therapeutic labeling, and tumor mutation profiling by qualified health care professionals per oncology professional guidelines. The statement says genomic findings outside that table are not prescriptive or conclusive for labeled use of any specific therapeutic product, and that xT CDx is a single-site assay performed at Tempus Labs, Inc., Chicago, IL. The record carries no supplement type or reason, so the original scope is described rather than a changed item. These are reported intended uses, not independent proof of safety or clinical effectiveness.

FDA approval order statement

Approval for the xT CDx. The device is a qualitative Next Generation Sequencing (NGS)-based in vitro diagnostic device intended for use in the detection of substitutions (single nucleotide variants (SNVs) and multi-nucleotide variants (MNVs)) and insertion and deletion alterations (INDELs) in 648 genes, as well as microsatellite instability (MSI) status, using DNA isolated from formalin-fixed paraffin embedded (FFPE) tumor tissue specimens, and DNA isolated from matched normal blood or saliva specimens, from previously diagnosed cancer patients with solid malignant neoplasms.The test is intended as a companion diagnostic (CDx) to identify patients who may benefit from treatment with the targeted therapies listed in the Companion Diagnostic Indications table in accordance with the approved therapeutic product labeling.Additionally, xT CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with previously diagnosed solid malignant neoplasms. Genomic findings other than those listed in the Companion Diagnostic Indications table are not prescriptive or conclusive for labeled use of any specific therapeutic product.xT CDx is a single-site assay performed at Tempus Labs, Inc., Chicago, IL.
Regulatory pathway
Original PMA
Clinical specialty
Pathology
Decision date
Apr 28, 2023

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P210011
Regulatory pathway
Premarket approval application
Product code
PQP
Decision code
APPR
Decision date
Apr 28, 2023
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Next generation sequencing oncology panel, somatic or germline variant detection system.

Product code
PQP
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P210011 received

    Application receipt date recorded by FDA.

  2. P210011 · FDA decision

    APPR

Timeline entries are records held by MedtechLedger for P210011. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P210011

Product / regulatory recordCompanyPathwayDecision dateSource
xT CDxP210011/S002
Tempus AI, Inc.PMA supplementSep 2, 2026FDA
xT CDxP210011/S006
Tempus AI, Inc.PMA supplementOct 23, 2026FDA

Explore the linked device profile

Other records with product code PQP

Product / regulatory recordCompanyPathwayDecision dateSource
Life Technologies CorporationPMA supplementNov 4, 2026FDA
MI Cancer SeekP240010/S007
Caris Life SciencesPMA supplementOct 16, 2026FDA
Foundation Medicine, Inc.PMA supplementSep 18, 2026FDA
Guardant360 CDxP200010/S029
Guardant Health, Inc.PMA supplementSep 18, 2026FDA
FoundationOne CDxP170019/S069
Foundation Medicine, Inc.PMA supplementSep 16, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Tempus AI, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
600 W Chicago Ave., Suite #510, Chicago, IL, 60654

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records